Calcium metabolism in sarcoidosis

C. E. Dent

Medical Unit, University College Hospital Medical School, London, W.C.1

Summary

Fifteen patients with hypercalcaemia and sarcoidosis have been studied. Twelve were males of average age 34; the three females averaged 53.

Cases included widely varying sarcoid manifestations, but five gave a clear history of rather excessive ingestion of low-dosage vitamin D preparations. The data confirm that in most cases there is an undue sensitivity to all the actions of vitamin D, the situation therefore mimicking vitamin D intoxication. Two patients volunteered to receive ultra-violet irradiation and became hypercalcaemic with corresponding clinical and biochemical changes.

Steroids make normal the calcium abnormalities just as they do in straight vitamin D intoxication. However, in three further patients the hypercalcaemia did not respond to steroids and was shown to be due to the presence of an over-acting parathyroid gland, removal of which corrected the abnormality. There are a sufficient number of other similar cases in the literature to suggest that the development of parathyroid adenomas is another even rarer complication of sarcoidosis which must be carefully distinguished from vitamin D sensitivity.

It has been known for some time that certain patients with sarcoidosis also manifest a disorder of calcium metabolism. This was discovered partly because they used to be treated with large doses of calciferol and it was obvious from the rapid intoxication which sometimes ensued that they could be unduly sensitive to this vitamin. It was then discovered that some manifested hypercalcaemia apparently spontaneously. Finally some of these patients presented with urinary stones and hypercalcuria, others with renal failure, which could not be explained as the result of involvement of the kidney by the sarcoid granulomas. These latter situations gave grounds for the suspicion that hypercalcaemia had been present previously even if not found to be present still. This was made even more likely by the occurrence in some of corneal calcification, a sign possibly pathognomonic of past or present hypercalcaemia.

My own interest in the problem arose from the need to distinguish such hypercalcaemic sarcoid patients from those with hypercalcaemia of other origins. The problem was early highlighted by a mis-diagnosis I made in 1950 of primary hyperparathyroidism in a patient who really had sarcoidosis. This latter patient manifested no clinical signs of sarcoidosis at the time of diagnosis although she developed a typical rash some years after I had advised her to have a neck exploration which of course was unsuccessful. This problem of differential diagnosis was not much helped by purely clinical studies. Some patients with primary hyperparathyroidism manifested remarkably few specific clinical features. Patients with hypercalcaemia as a complication of sarcoidosis did not belong to any particular clinical type. The only small help came from a study of their age distribution which in a few cases tended to be lower than usual, of their sex which was predominantly male, and from the fact that a high proportion had been taking vitamin D for some reason or other in doses that would not produce hypercalcaemia in a normal patient. I now summarize some data for our fifteen hypercalcaemic sarcoid patients, which includes that of our first five published already (Dent, 1958): ten had corneal calcification, one iridocyclitis, five lymphadenopathy, five splenomegaly, nine miliary chest shadowing, one osteitis cystoides multiplex, six various rashes, five gave a clear history of self medication with vitamin D preparations. There were twelve males and three females, the average age 34 years in the males (who included the three youngest of 14, 15 and 23 years), 53 years in the females. The maintenance dose of steroid on follow up was 25–62.5 mg of cortisone, or 40 mg of hydrocortisone or, in one case, 6 mg of prednisone.

We experimented very early with the use of cortisone as a means of differential diagnosis and it soon became clear that patients with hypercalcaemic sarcoidosis responded well to cortisone at a dose of 50 mg 8-hourly for 10 days, the plasma calcium falling, often to normal, during this time (Fig. 1) and it could be kept normal with a much diminished dose, sometimes of the order of 25–50 mg/day such as is only useful otherwise in the maintenance of Addison’s disease (see above). Nevertheless on this...
small dose most of the sarcoïd lesions also disappeared in the next few months as if to suggest that the lesions were particularly sensitive in these patients. In primary hyperparathyroidism the hypercalcaemia was not thus affected (Dent & Watson, 1968).

Further studies of this calcium abnormality at U.C.H. (Anderson et al., 1954) and independently by Henneman and his group in the U.S.A. (Henneman et al., 1956) showed that the hypercalcaemic state in sarcoïdosis closely resembled that of vitamin D intoxication. Furthermore some patients with sarcoïdosis without hypercalcaemia could be induced to develop this hypercalcaemic state by rather small doses of vitamin D. These observations helped to explain another early clinical finding which was difficult to investigate fully namely that some of these patients with sarcoïdosis became ill when exposed to bright sunlight. We have had the opportunity of irradiating with artificial UV light two patients (Figs. 2 and 3) who volunteered to test this effect, one under full calcium balance control. It can be seen that both these patients became hypercalcaemic with the irradiation. The balance changes (Fig. 3) resembled those of vitamin D intoxication, exactly as would be obtained in a normal person given very large doses of vitamin D. Of even more interest was the fact that giving cortisone reversed all these metabolic changes even though the irradiation was being continued. Hence we think we have proved that there is a true sensitivity to vitamin D taken either orally or from sunlight in these particular patients with sarcoïdosis and that this is in some way antagonized by cortisone. This result, by the way, led to the investigation of the effect of cortisone in ordinary vitamin D intoxication in patients with other diseases. It was found to be quickly effective in reversing all the signs and symptoms, in other words, cortisone is an antidote to vitamin D intoxication.

We are still puzzled as to the possible mechanism by which the chronic sarcoïd granuloma sometimes produces this sensitization to vitamin D, but current work on its metabolism suggests possible explanations. We now know that vitamin D has to be converted to 25-hydroxycholecalciferol before it can exert its usual action (Blunt, De Luca & Schnoes, 1968). In some cases of so-called 'vitamin D resistance' (for instance in renal failure) this conversion is somehow inhibited (Avioli et al., 1968). One only has to postulate that in the relevant patients with sarcoïdosis the conversion is facilitated, a theory which is open to experimental verification by existing methods. This theory might also explain another of our clinical observations, namely, that sarcoïd patients who develop chronic uraemia do not seem to get renal osteodystrophy.

We have used the cortisone test in all our fifteen patients with hypercalcaemic sarcoïdosis. They all responded well except one who had marked liver involvement. He responded better to hydrocortisone, perhaps because his liver was incapable of converting the cortisone given to the active hydrocortisone compound. We therefore now use hydrocortisone instead of cortisone for our standard test in the

---

**Fig. 1.** Response of hypercalcaemic sarcoïdosis patients to standard test with cortisone or hydrocortisone. Six patients showed a typical response, namely, a rapid fall to normal in plasma calcium level. The seventh who maintained very high fluctuating levels was later shown to have a parathyroid adenoma, removal of which led to a fall to normal of his plasma calcium (Dent & Watson, 1966). O = Cortisone 30 mg 8-hourly, ● Hydrocortisone 40 mg 8-hourly.

**Fig. 2.** Effects of UV and corticosteroid on patient with sarcoïdosis. This patient had some months previously taken small doses of vitamin D and was slightly hypercalcaemic on admission. The first course of steroid lowered this, it was then raised with UV irradiation, and again lowered, the UV being continued, when steroid was again given. The dose of vitamin D thus given, while effectively antirachitic in normals, is far too small to produce hypercalcaemia in a normal person.

---
Calcium metabolism in sarcoidosis

The differential diagnosis may however be more difficult than this for we have had three cases of our own and have seen several elsewhere and in the literature in which patients with sarcoidosis identified by biopsy and other means had a hypercalcaemia that was not responsive to hydrocortisone (one is shown in Fig. 2). All these patients were found to have parathyroid adenomas as well, which when removed dealt with the hypercalcaemia adequately, thus showing that the adenoma was the entire cause in these patients. I believe that finding three such patients in our series is likely to be more than a coincidence and am speculating that sarcoidosis may sometimes stimulate the parathyroid glands by an unknown mechanism to produce adenomas. If this is confirmed there will be yet another metabolic complication to add to that of the vitamin D sensitivity and it is interesting to wonder if there may be some link between these two.

Acknowledgment
The author wishes to thank Dr P. Heaf for permission to use data from his patient shown in Fig. 2.

References
Calcium metabolism in sarcoidosis

C. E. Dent

doi: 10.1136/pgmj.46.538.471

Updated information and services can be found at:
http://pmj.bmj.com/content/46/538/471

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/